AUSTIN, Texas, April 24, 2012 /PRNewswire/ -- Luminex
Corporation (NASDAQ: LMNX) today announced the expansion of two
dedicated groups within its organization: the Life Science
and the Biodefense Groups, each with focused initiatives on the
development of Luminex technology into these important market
segments. While already participating in these markets,
further investment in these groups provides additional growth
opportunities to build Luminex leadership, advance scientific
research and provide solutions for these evolving markets.
(Logo:
http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)
Life Sciences
The Luminex Life Sciences Group provides custom, high-throughput
assay solutions for gene expression and genotyping research.
"Our technology offers researchers a unique combination of benefits
that both accelerate understanding of complex biological systems
and reduce costs," said Tom Copa,
vice president of Luminex Life Sciences. "Using our systems,
researchers no longer need to choose between the number of
transcripts or alleles measured and the number of samples processed
per project. They can have large numbers of both."
The need to validate discoveries made through sequencing and
microarrays, combined with the need to improve early compound
screening and ADMET studies in drug discovery, is driving the
desire to measure many genes across large numbers of samples.
To address this unmet need, Luminex Life Sciences has launched the
FlexScript™ LDA gene expression assay, which allows researchers to
measure the expression of a custom set of genes. Combined
with the FLEXMAP 3D® instrument, FlexScript LDA empowers
researchers to assay up to 500 genes per sample, with a throughput
of thousands of samples per day.
Biodefense
The additional investment in the Luminex Biodefense Group
further accelerates the company's biothreat detection applications
in development. "There are many exciting opportunities where
Luminex technology can make a significant impact," said
Amy Altman, Ph.D. and vice president
of Luminex's Biodefense group. "Unlike other biothreat
detection systems, our technology has the ability to simultaneously
detect multiple potential agents and process multiple samples with
greater throughput. This unique feature provides significant
power and speed in biothreat detection."
In addition to ongoing initiatives in the area of environmental
detection, Luminex is also involved in biodefense-related programs
and grants aimed at the development of a hand-held multiplex
point-of-care diagnostic platform for the detection of biothreat
agent exposure and biosurveillance.
"We are excited by the growth opportunities these evolving
market segments represent. The expansion in both biodefense
and life science reflects our commitment to broadening our
leadership in areas beyond life science research proteins and
clinical diagnostics and developing solutions to meet the varied
needs of our diverse customer base," said Patrick J. Balthrop, president and chief
executive officer of Luminex. "Our mission is to improve the
health, safety and quality of life for people around the world.
These initiatives highlight and support that effort."
The activities of these groups are primarily associated with the
development and sale of assay products and therefore will be
reported as part of Luminex's Assays and Related Products
Segment.
About Luminex Corporation
Luminex is committed to applying its passion for innovation to
advancing healthcare and research worldwide. We are transforming
global healthcare and life-science research through the
development, manufacturing, and marketing of proprietary
instruments and assays utilizing our xMAP® open-architecture,
multi-analyte platform, and our MultiCode® real-time polymerase
chain reaction (PCR) and multiplex PCR-based technologies, that
deliver cost-effective and rapid results to clinicians and
researchers. Our technology is commercially available worldwide and
in use in leading clinical laboratories as well as major
pharmaceutical, diagnostic, biotechnology and life-science
companies. We are meeting the needs of customers in markets as
diverse as clinical diagnostics, pharmaceutical drug discovery,
biomedical research including genomic and proteomic research,
personalized medicine, bio-defense research and food safety. For
further information on Luminex Corporation and the latest advances
in multiplexing using award winning technology please visit our
website at http://www.luminexcorp.com.
Contacts
|
|
Corporate:
|
Media:
|
Harriss T.
Currie
|
Mimi
Torrington
|
Chief
Financial Officer and Vice President,
Finance
|
Director,
Marketing Communications
|
Luminex
Corporation
|
Luminex
Corporation
|
hcurrie@luminexcorp.com
|
mtorrington@luminexcorp.com
|
512.219.8020
|
512.219.8020
|
|
|
Investors:
|
Aaron
DeLucia
|
Matthew
Scalo
|
Porter
Novelli
|
Sr.
Director, Investor
Relations
|
Aaron.DeLucia@porternovelli.com
|
Luminex
Corporation
|
512.241.2249
|
mscalo@luminexcorp.com
|
|
512.219.8020
|
|
SOURCE Luminex Corporation